Filter

Refine by date

—

Refine by access

  • Print
  • Save

Search Results

You are looking at 1 - 1 of 1 items for

  • Author: Ryo Morimoto x
  • Refine by access: All content x
Clear All Modify Search
Ryo Morimoto
Search for other papers by Ryo Morimoto in
Google Scholar
PubMed Close
,
Fumitoshi Satoh
Search for other papers by Fumitoshi Satoh in
Google Scholar
PubMed Close
,
Osamu Murakami
Search for other papers by Osamu Murakami in
Google Scholar
PubMed Close
,
Takuo Hirose Division of Nephrology, Department of Clinical Pharmacology and Therapeutics, Department of Urology, Department of Pathology and Histotechnology, Department of Pathology, Department of Endocrinology and Applied Medical Science, Endocrinology, and Vascular Medicine, Department of Medicine, Tohoku University Graduate School of Medicine, Sendai, Miyagi 980-8574, Japan

Search for other papers by Takuo Hirose in
Google Scholar
PubMed Close
,
Kazuhito Totsune Division of Nephrology, Department of Clinical Pharmacology and Therapeutics, Department of Urology, Department of Pathology and Histotechnology, Department of Pathology, Department of Endocrinology and Applied Medical Science, Endocrinology, and Vascular Medicine, Department of Medicine, Tohoku University Graduate School of Medicine, Sendai, Miyagi 980-8574, Japan

Search for other papers by Kazuhito Totsune in
Google Scholar
PubMed Close
,
Yutaka Imai Division of Nephrology, Department of Clinical Pharmacology and Therapeutics, Department of Urology, Department of Pathology and Histotechnology, Department of Pathology, Department of Endocrinology and Applied Medical Science, Endocrinology, and Vascular Medicine, Department of Medicine, Tohoku University Graduate School of Medicine, Sendai, Miyagi 980-8574, Japan

Search for other papers by Yutaka Imai in
Google Scholar
PubMed Close
,
Yoichi Arai Division of Nephrology, Department of Clinical Pharmacology and Therapeutics, Department of Urology, Department of Pathology and Histotechnology, Department of Pathology, Department of Endocrinology and Applied Medical Science, Endocrinology, and Vascular Medicine, Department of Medicine, Tohoku University Graduate School of Medicine, Sendai, Miyagi 980-8574, Japan

Search for other papers by Yoichi Arai in
Google Scholar
PubMed Close
,
Takashi Suzuki Division of Nephrology, Department of Clinical Pharmacology and Therapeutics, Department of Urology, Department of Pathology and Histotechnology, Department of Pathology, Department of Endocrinology and Applied Medical Science, Endocrinology, and Vascular Medicine, Department of Medicine, Tohoku University Graduate School of Medicine, Sendai, Miyagi 980-8574, Japan

Search for other papers by Takashi Suzuki in
Google Scholar
PubMed Close
,
Hironobu Sasano Division of Nephrology, Department of Clinical Pharmacology and Therapeutics, Department of Urology, Department of Pathology and Histotechnology, Department of Pathology, Department of Endocrinology and Applied Medical Science, Endocrinology, and Vascular Medicine, Department of Medicine, Tohoku University Graduate School of Medicine, Sendai, Miyagi 980-8574, Japan

Search for other papers by Hironobu Sasano in
Google Scholar
PubMed Close
,
Sadayoshi Ito
Search for other papers by Sadayoshi Ito in
Google Scholar
PubMed Close
, and
Kazuhiro Takahashi Division of Nephrology, Department of Clinical Pharmacology and Therapeutics, Department of Urology, Department of Pathology and Histotechnology, Department of Pathology, Department of Endocrinology and Applied Medical Science, Endocrinology, and Vascular Medicine, Department of Medicine, Tohoku University Graduate School of Medicine, Sendai, Miyagi 980-8574, Japan

Search for other papers by Kazuhiro Takahashi in
Google Scholar
PubMed Close

Adrenomedullin 2/intermedin (AM2/IMD) is a new member of calcitonin/calcitonin gene-related peptide family. AM is expressed in various tumors including adrenocortical tumors and modulates tumor growth. The AM2/IMD expression has not been studied, however, in adrenal tumors. The expression of AM2/IMD and AM was therefore studied in human adrenal tumors and attached non-neoplastic adrenal tissues by immunocytochemistry (ICC). Immunoreactive (IR)–AM2/IMD was measured by RIA. Furthermore, the expression of AM2/IMD and its receptor components, calcitonin receptor-like receptor (CRLR), and receptor activity-modifying proteins (RAMPs) 1, 2, and 3 mRNA in these tissues was studied by reverse transcription PCR (RT-PCR). ICC showed that AM2/IMD and AM immunoreactivities were localized in adrenocortical tumors and pheochromocytomas. AM2/IMD and AM immunoreactivities were detected in medulla of attached non-neoplastic tissues, while the degree of immunoreactivity for AM2/IMD and AM in cortices of attached adrenals was relatively weak or undetectable. RIA detected IR-AM2/IMD in adrenal tumors (0.414±0.12 to 0.786±0.27 pmol/g wet weight, mean±s.e.m.) and attached adrenal tissues (0.397±0.052 pmol/g wet weight). Reverse-phase high-performance liquid chromatography showed one broad peak eluted in the similar position to synthetic AM2/IMD with several minor peaks. RT-PCR showed expression of AM2/IMD, CRLR, and RAMP1, RAMP2, and RAMP3 mRNA in tissues of adrenal tumors and attached adrenal glands. In conclusion, AM2/IMD is expressed in human adrenal tumors and attached non-neoplastic adrenal tissues and may play (patho-)physiological roles in normal and neoplastic adrenals as an autocrine/paracrine regulator.

Article Type:
Research Article
DOI:
https://doi.org/10.1677/JOE-08-0103
Volume/Issue:
Volume 198: Issue 1
Free access